- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03643263
Exhaled Breath Condensate Assessment in Stable Non-Cystic Fibrotic Bronchiectasis
July 7, 2022 updated by: Jin-Fu Xu, Shanghai Pulmonary Hospital, Shanghai, China
Exploring the Relationship Between pH of Exhaled Breath Condensate and Disease Severity as Well as Prognosis of Bronchiectasis
The measurement of markers in the expired breath condensate has proven to be a useful method for assessing and monitoring airway inflammation.
The aim of this study is to determine the amounts of pH in the expired breath condensate of patients with bronchiectasis, and the relationship between pH and the severity of bronchiectasis.
Study Overview
Status
Completed
Conditions
Detailed Description
The aim of this study is to determine the amounts of pH in the expired breath condensate of patients with bronchiectasis, and the relationship between pH and the severity of bronchiectasis.
Further clarify the link between EBC pH and the risk of future acute exacerbations, mortality and lung function decline through a one-year follow-up.
Hoping to explore new validated biomarkers of the disease severity and progression in bronchiectasis.
During the observation, EBC pH and other valid indicators will be measured when patients were enrolled.
Study Type
Observational
Enrollment (Actual)
121
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Shanghai Pulmonary Hospital , Tongji University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The age of all subjects are older than 18 .
The diagnosis of bronchiectasis need reference to the guideline published by BTS in 2010 or 2012 China bronchiectasis expert consensus, clinical symptoms of cough and expectoration, with or without intermittent hemoptysis, and chest CT showed bronchiectasis there.All patients were clinically stable and had no evidence of exacerbation for at least 4 weeks before the study and had a negative history of allergy.
None of patients had reversibility with inhaled salbutamol of 12% or more of predicted FEV1; All normal subjects had a negative history of allergy and normal lung function, they have no history of any lung disease (except for the history of pneumonia in the past time and small pulmonary nodules).
Description
Inclusion Criteria:Each subject must meet all of the following criteria to be included in this study:
- Willing to join in and sign the informed consent form.
- Age>18 years, the diagnosis of bronchiectasis need reference to the definition of "non-cystic fibrosis bronchiectasis guideline" published by British Thoracic Society in 2010 or 2012 China bronchiectasis expert consensus, clinical symptoms of cough and expectoration, with or without intermittent hemoptysis, and chest CT showed bronchiectasis there.
- All patients were clinically stable and had no evidence of infection or acute infective exacerbation (lower or upper respiratory tract) for at least 4 weeks before the study.
- Patients with good compliance: the subject must be willing to follow the test plan requirements in the research center to complete all the assessment of the visit.
Control Subjects:
- All normal subjects had a negative history of allergy (negative skin prick tests to common allergens);
- Normal lung function, and normal bronchial reactivity.
- No history of any lung disease (except for the history of pneumonia in the past time and small pulmonary nodules).
Exclusion Criteria:Subjects who meet any of the following criteria should be excluded from this study:
- Patients with a history of other respiratory diseases (cystic fibrosis, allergic bronchopulmonary aspergillosis, asthma, 1-antitrypsin deficiency, pulmonary tuberculosis, COPD, lung cancer, interstitial lung disease)and atopic diseases were excluded;
- Serious comorbidities (chronic renal failure, hepatic disease, etc.) ;
- Patients were on inhaled or oral mucolytics, or were receiving oxygen therapy or long-term oral antibiotics;
- Poor compliance or cannot cooperate judged by doctors;
- Participated in other clinical trials for nearly three months;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exhaled breath condensate pH and the disease severity
Time Frame: One year
|
The Relationship between pH of exhaled breath condensate and disease severity of Bronchiectasis
|
One year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BSI scores
Time Frame: 30 days
|
Assessment of the non-cystic fibrosis bronchiectasis severity according by the BSI score at the time of admission
|
30 days
|
|
SGRQ scores
Time Frame: 30 days
|
Assessment of the quality of life of non-cystic fibrosis bronchiectasis according by the St.George respiratory questionnaire at the time of admission
|
30 days
|
|
Lung function (FEV1 %, FVC %, FEV1/FVC %)
Time Frame: One year
|
Lung function will be measured at the time of admission
|
One year
|
|
Sputum and peripheral blood inflammatory index (including IL-6, IL-8, IL-1β, TNF-a)
Time Frame: One year
|
Sputum and peripheral blood inflammatory index will be assessed at the time of admission
|
One year
|
|
Sputum neutrophil cell
Time Frame: One year
|
Sputum neutrophil cell count and percentage will be assessed at the time of admission
|
One year
|
|
Sputum bacteriological evaluation
Time Frame: One year
|
Sputum bacteriological (pseudomonas aeruginosa and others) will be evaluated at the time of admission
|
One year
|
|
Blood gases parameters (PaO2, SaO2, PaCO2, pH)
Time Frame: 30 days
|
Blood gases will be assessed at the time of admission
|
30 days
|
|
Chest high-resolution computed tomography (CT)
Time Frame: One year
|
Chest high-resolution computed tomography (CT) will be evaluated at the time of admission
|
One year
|
|
Frequency of acute exacerbation during one year
Time Frame: 30 days
|
The number of acute exacerbation will be recorded by telephone follow-up monthly.
The definition of acute exacerbation: if there are at least one symptoms (increased sputum volume or purulent sputum, increased dyspnea, increased cough, lung function decline, increased fatigue) or new symptoms (fever, pleurisy, hemoptysis, require antimicrobial therapy), then prompted acute exacerbation.
|
30 days
|
|
Time to first exacerbation during the one-year follow up
Time Frame: 30 days
|
The time to first exacerbation within one year after start of the study
|
30 days
|
|
The number of hospitalizations for exacerbation
Time Frame: 30 days
|
The number of hospitalizations for exacerbation within one year after start of the study
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 25, 2018
Primary Completion (Actual)
July 2, 2020
Study Completion (Actual)
July 2, 2020
Study Registration Dates
First Submitted
August 21, 2018
First Submitted That Met QC Criteria
August 21, 2018
First Posted (Actual)
August 22, 2018
Study Record Updates
Last Update Posted (Actual)
July 11, 2022
Last Update Submitted That Met QC Criteria
July 7, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20180323
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.